14-3-3: A Case Study in PPI Modulation

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 Jun 13

PMID 29890630

Citations 19

Authors

Alice Ballone

Federica Centorrino

Christian Ottmann

Affiliations

Soon will be listed here.

Abstract

In recent years, targeting the complex network of protein⁻protein interactions (PPIs) has been identified as a promising drug-discovery approach to develop new therapeutic strategies. 14-3-3 is a family of eukaryotic conserved regulatory proteins which are of high interest as potential targets for pharmacological intervention in human diseases, such as cancer and neurodegenerative and metabolic disorders. This viewpoint is built on the “hub” nature of the 14-3-3 proteins, binding to several hundred identified partners, consequently implicating them in a multitude of different cellular mechanisms. In this review, we provide an overview of the structural and biological features of 14-3-3 and the modulation of 14-3-3 PPIs for discovering small molecular inhibitors and stabilizers of 14-3-3 PPIs.

Citing Articles

Site-specific molecular glues for the 14-3-3/Tau pS214 protein-protein interaction reversible covalent imine tethering.

Oberheide A, van den Oetelaar M, Scheele J, Borggrafe J, Engelen S, Sattler M RSC Med Chem. 2025; .

PMID: 40070456 PMC: 11892739. DOI: 10.1039/d4md00833b.

Development of a NanoBRET assay for evaluation of 14-3-3σ molecular glues.

Vickery H, Virta J, Konstantinidou M, Arkin M SLAS Discov. 2024; 29(5):100165.

PMID: 38797286 PMC: 11774552. DOI: 10.1016/j.slasd.2024.100165.

Mechanistic Insights into the Function of 14-3-3 Proteins as Negative Regulators of Brassinosteroid Signaling in Arabidopsis.

Obergfell E, Hohmann U, Moretti A, Chen H, Hothorn M Plant Cell Physiol. 2024; 65(10):1674-1688.

PMID: 38783418 PMC: 11558545. DOI: 10.1093/pcp/pcae056.

Pathogenic mutations of human phosphorylation sites affect protein-protein interactions.

Rrustemi T, Meyer K, Roske Y, Uyar B, Akalin A, Imami K Nat Commun. 2024; 15(1):3146.

PMID: 38605029 PMC: 11009412. DOI: 10.1038/s41467-024-46794-8.

Covalent 14-3-3 Molecular Glues and Heterobifunctional Molecules Against Nuclear Transcription Factors and Regulators.

Shao Q, Duong T, Park I, Nomura D bioRxiv. 2023; .

PMID: 37986959 PMC: 10659333. DOI: 10.1101/2023.11.06.565850.

References

Pozuelo Rubio M, Geraghty K, Wong B, Wood N, Campbell D, Morrice N . 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J. 2004; 379(Pt 2):395-408. PMC: 1224091. DOI: 10.1042/BJ20031797. View

Cromm P, Wallraven K, Glas A, Bier D, Furstner A, Ottmann C . Constraining an Irregular Peptide Secondary Structure through Ring-Closing Alkyne Metathesis. Chembiochem. 2016; 17(20):1915-1919. PMC: 5096054. DOI: 10.1002/cbic.201600362. View

Oecking C, Eckerskorn C, Weiler E . The fusicoccin receptor of plants is a member of the 14-3-3 superfamily of eukaryotic regulatory proteins. FEBS Lett. 1994; 352(2):163-6. DOI: 10.1016/0014-5793(94)00949-x. View

Richter A, Rose R, Hedberg C, Waldmann H, Ottmann C . An optimised small-molecule stabiliser of the 14-3-3-PMA2 protein-protein interaction. Chemistry. 2012; 18(21):6520-7. DOI: 10.1002/chem.201103761. View

De Vries-van Leeuwen I, da Costa Pereira D, Flach K, Piersma S, Haase C, Bier D . Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface. Proc Natl Acad Sci U S A. 2013; 110(22):8894-9. PMC: 3670367. DOI: 10.1073/pnas.1220809110. View

Ottmann C, Weyand M, Sassa T, Inoue T, Kato N, Wittinghofer A . A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A. J Mol Biol. 2009; 386(4):913-9. DOI: 10.1016/j.jmb.2009.01.005. View

Chen S, Synowsky S, Tinti M, Mackintosh C . The capture of phosphoproteins by 14-3-3 proteins mediates actions of insulin. Trends Endocrinol Metab. 2011; 22(11):429-36. DOI: 10.1016/j.tem.2011.07.005. View

Lopez-Girona A, Furnari B, Mondesert O, Russell P . Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature. 1999; 397(6715):172-5. DOI: 10.1038/16488. View

Wang B, Yang H, Liu Y, Jelinek T, Zhang L, Ruoslahti E . Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry. 1999; 38(38):12499-504. DOI: 10.1021/bi991353h. View

10.

Kamata K, Okubo M, Ishigamori E, Masaki Y, Uchida H, Watanabe K . Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals. Transplantation. 1983; 35(2):144-9. DOI: 10.1097/00007890-198302000-00007. View

11.

Shimada T, Fournier A, Yamagata K . Neuroprotective function of 14-3-3 proteins in neurodegeneration. Biomed Res Int. 2013; 2013:564534. PMC: 3865737. DOI: 10.1155/2013/564534. View

12.

Bartel M, Schafer A, Stevers L, Ottmann C . Small molecules, peptides and natural products: getting a grip on 14-3-3 protein-protein modulation. Future Med Chem. 2014; 6(8):903-21. DOI: 10.4155/fmc.14.47. View

13.

Inoue T, Higuchi Y, Yoneyama T, Lin B, Nunomura K, Honma Y . Semisynthesis and biological evaluation of a cotylenin A mimic derived from fusicoccin A. Bioorg Med Chem Lett. 2018; 28(4):646-650. DOI: 10.1016/j.bmcl.2018.01.030. View

14.

Gardino A, Smerdon S, Yaffe M . Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol. 2006; 16(3):173-82. DOI: 10.1016/j.semcancer.2006.03.007. View

15.

Corradi V, Mancini M, Santucci M, Carlomagno T, Sanfelice D, Mori M . Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case. Bioorg Med Chem Lett. 2011; 21(22):6867-71. DOI: 10.1016/j.bmcl.2011.09.011. View

16.

Bier D, Mittal S, Bravo-Rodriguez K, Sowislok A, Guillory X, Briels J . The Molecular Tweezer CLR01 Stabilizes a Disordered Protein-Protein Interface. J Am Chem Soc. 2017; 139(45):16256-16263. PMC: 5691318. DOI: 10.1021/jacs.7b07939. View

17.

Molzan M, Schumacher B, Ottmann C, Baljuls A, Polzien L, Weyand M . Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol Cell Biol. 2010; 30(19):4698-711. PMC: 2950525. DOI: 10.1128/MCB.01636-09. View

18.

Nooren I, Thornton J . Diversity of protein-protein interactions. EMBO J. 2003; 22(14):3486-92. PMC: 165629. DOI: 10.1093/emboj/cdg359. View

19.

Hashiguchi M, Sobue K, Paudel H . 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem. 2000; 275(33):25247-54. DOI: 10.1074/jbc.M003738200. View

20.

Aitken A . 14-3-3 proteins: a historic overview. Semin Cancer Biol. 2006; 16(3):162-72. DOI: 10.1016/j.semcancer.2006.03.005. View